# US 2021/0275601 A1 · Ldl-cholesterol-lowering cell extract and food supplement

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275601 A1
- Document ID: US20210275601A1
- Status: Published application
- Kind: A1
- Application number: 17/314,090
- Filed: 2021-05-07
- Published: 2021-09-09
- Earliest claimed: 2017-06-15
- Assignees: ezCol B.V.
- Applicants: ezCol B.V.
- Inventors: Ruddy Wattiez; Felice Mastroleo; Robertus Christiaan Josephus Suters
- Web page: https://patentgrep.com/patent/US20210275601A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A23L 33/13: Nucleic acids or derivatives thereof (A23L33/145 takes precedence)
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 47/06: Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/06: Antihyperlipidemics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An extract of Rhodospirillum rubrum includes rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10. Such an extract could be used as a medicament, for lowering of LDL-cholesterol in blood plasma of a subject and/or for subjects who suffer from or have an increased risk of one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemia, or infection.

## Claims

### Claim 1

An extract of Rhodospirillum rubrum, comprising rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10.

### Claim 2 (depends on 1)

The petroleum ether extract of Rhodospirillum rubrum according to claim 1, for use as a medicament.

### Claim 3 (depends on 1)

The petroleum ether extract of Rhodospirillum rubrum according to claim 1, for use in the lowering of LDL-cholesterol in blood plasma of a subject.

### Claim 4 (depends on 1)

The petroleum ether extract of Rhodospirillum rubrum according to claim 1, for use in a method for the lowering of LDL-cholesterol in blood plasma of a subject.

### Claim 5 (depends on 1)

The petroleum ether extract of Rhodospirillum rubrum according to claim 1, for use in the lowering of LDL-cholesterol in blood plasma of a subject or for use in a method for the lowering of LDL-cholesterol in blood plasma of a subject, wherein the subject suffers from or has an increased risk for any one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemic, or infection.

### Claim 6 (depends on 1)

The petroleum ether extract of Rhodospirillum rubrum according to claim 1, wherein the extract is administered orally.

### Claim 7 (depends on 1)

A food supplement with LDL-cholesterol lowering properties, comprising the petroleum ether extract of Rhodospirillum rubrum according to claim 1.

### Claim 8 (depends on 7)

A foodstuff comprising the food supplement according to claim 7.

### Claim 9 (depends on 1)

A method for the production of the petroleum ether extract of Rhodospirillum rubrum of claim 1, comprising the steps of:
a) providing Rhodospirillum rubrum cells
b) providing a biphasic mixture having about a 1:1 ratio by volume of petroleum ether that has a boiling point between 60° C. and 80° C. and methanol that comprises about 0.03% by weight of sodium chloride;
c) mixing the cells of step a) with the biphasic mixture of step b) for about 1 to 3 hours at a temperature between 15° C. and 25° C.;
d) separating the petroleum ether phase from the methanol phase of the biphasic mixture; and
e) isolating the petroleum ether phase, thereby obtaining the petroleum ether extract of Rhodospirillum rubrum.

### Claim 10

A method of treating a subject in need thereof, the method comprising administering an extract of Rhodospirillum rubrum, comprising rhodovibrin, 1-hydroxyspirilloxanthin, 3,4-didehydrorhodopin, chloroxanthin, bacteriopheophytin a, rhodopin, spirilloxanthin, 3,4-dihydrospirilloxanthin, phytyl derivative of bacteriopheophytin a, ubiquinol-10, ubiquinone-9, ubiquinone-10 and rhodoquinone-10.

### Claim 11 (depends on 10)

The method of claim 10, wherein the method lowers LDL-cholesterol in blood plasma of the subject.

### Claim 12 (depends on 10)

The method of claim 10, wherein the subject suffers from or has an increased risk for one or more of cardiovascular disease, atherosclerosis, dyslipidemia, arteriosclerosis, hypercholesterolemia, familial hypercholesterolemia, hyperlipidemia, an LDL plasma level of at least 70 mg/dL, a total cholesterol level of at least 200 mg/dL, an Lp(a) level of at least 14 mg/dL, inflammation, inflammatory disease, ischemia, or infection.

### Claim 13 (depends on 10)

The method of claim 10, wherein the method comprises administering the extract orally.